Product Introduction
Bioactivity


英文名: Milatuzumab

描述: Milatuzumab (MEDI-115) 是一种人源化抗 CD74 单克隆抗体。Milatuzumab 促使自由基氧的产生和线粒体膜电位的丧失，可降低 CD20/CD74 聚集体和细胞粘附，诱导细胞死亡。

体外活性: Milatuzumab (5 μg/mL; 8-48 hours) enhanced cell death in MCL cell lines and primary patient tumor cells[1].In Jeko, Mino, and SP-53 cells, milatuzumab (5 μg/mL; 0.5-2 h) mediated cytotoxicity, depending in part on ROS production and loss of mitochondrial transmembrane potential[1].Milatuzumab (5 μg/mL; 4 hours) inhibited the NF-κB pathway and induced apoptosis. The mechanism of apoptosis was not related to caspase cleavage, Bcl-2 family member disorder, or autophagy induction[1].

体内活性: 通过每3天一次的腹腔注射，以每天15 mg/kg的剂量给药，milatuzumab显著提高了携带Jeko癌细胞的女性SCID小鼠的存活率。此外，在这个小鼠模型中，Milatuzumab与Rituximab显示出了协同作用[1]。

存储条件: store at low temperaturestore at -80°C

关键字: MEDI115 | Milatuzumab | MEDI 115